Myriad Genetics expanded its partnership with BioMarin Pharmaceutical to use Myriad's myChoice HRD companion diagnostic test to identify which cancer patients are the best fit for BioMarin's talazoparib.
A research team at the National University of Singapore has published a paper on a novel strategy to prevent progression of inflammation-associated cancers.
Taiwan-based ACT Genomics raked in $8 million in the company's first private funding round, giving the company a boost as it looks to ramp up development for its molecular diagnostic cancer assays.
Roche snatched up Germany's Signature Diagnostics to get its hands on the company's next-generation sequencing technology, advancing its cancer testing portfolio and riding a wave of recent acquisitions.
Oncology investigator Xiaoyang Qi says that he's wrapped another animal study that demonstrates the potential of a combination of cellular components into a treatment that's able to vanquish cancer cells.
Trovagene, developer of a urine-based cancer diagnostic, announced last week plans to sell 4,444,444 shares of common stock for $20 million. The San Diego-based company makes technology for detecting cell-free DNA and RNA resulting from diseased cell death in the urine of cancer patients.
North Carolina's G1 Therapeutics hauled in $33 million to advance a headline-grabbing approach to cancer treatment, helping the biotech hit the gas in a space otherwise dominated by Big Pharma.
Myriad Genetics is throwing in the towel in its fight to stop other companies from offering diagnostic tests that spot specific genes known to be associated with a higher risk of breast cancer.
The National Cancer Centre Singapore will brief on the status of a first-in-human clinical trial using an adenovirus under a protocol endorsed by the U.S. Food and Drug Administration and Singapore's Health Sciences Authority, highlighting the wealthy city-state's push to be a leader in early stage clinical trials in Asia.
San Diego-based oncology diagnostics outfit Biocept is teaming up with Insight Genetics of Nashville to develop an improved diagnostic for the most common type of lung cancer.